13D/13G Filings - Tetragon Financial Management LP

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2024-01-31
4:10 pm
Purchase
2023-12-31 13G Freeline Therapeutics Holdings plc
FRLN
Tetragon Financial Management LP 6,375,000
9.800%
6,375,000increase
(New Position)
Filing
History
2024-01-31
4:10 pm
Sale
2023-12-31 13G Autolus Therapeutics plc
AUTL
Tetragon Financial Management LP 8,000,000
4.600%
-1,461,883decrease
(-15.45%)
Filing
History
2023-03-20
09:13 am
Purchase
2023-03-09 13G Autolus Therapeutics plc
AUTL
Tetragon Financial Management LP 9,461,883
5.500%
9,461,883increase
(New Position)
Filing
History
2023-01-31
4:15 pm
Purchase
2022-12-31 13G Freeline Therapeutics Holdings plc
FRLN
Tetragon Financial Management LP 266,667
6.200%
20,000increase
(+8.11%)
Filing
History
2022-12-08
12:42 pm
Unchanged
2022-11-28 13D Applied Genetic Technologies Corporation
AGTC
Tetragon Financial Management LP 0
0.000%
0
(Unchanged)
Filing
History
2022-03-21
11:10 am
Purchase
2022-03-10 13G Freeline Therapeutics Holdings plc
FRLN
Tetragon Financial Management LP 246,667
6.100%
246,667increase
(New Position)
Filing
History